Effect of Avastin combined with preoperative FOLFOX chemotherapy on the prognosis of patients with locally advanced rectal cancer
10.3969/j.issn.1005-1678.2017.05.085
- VernacularTitle:安维汀联合FOLFOX方案术前化疗对局部进展期直肠癌患者预后的影响
- Author:
Zhengxi WU
;
Long LI
;
Zhenhai GUO
;
Xueming XU
;
Zhiye ZHANG
;
Jianfeng LI
;
Minyu JU
- Keywords:
locally advanced rectal cancer;
FOLFOX regimen;
bevacizumab;
cases of remission;
survival rate
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(5):257-259,262
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of Avastin (bevacizumab) combined with preoperative FOLFOX neoadjuvant chemotherapy on the prognosis of patients with locally advanced rectal cancer (LARC).MethodsA total of 80 cases of patients with LARC treated with total mesorectal excision (TME) in our hospital from January 2013 to January 2016 were randomly divided into the control group and the observation group, 40 cases in each group.The control group were treated with preoperative FOLFOX chemotherapy while the observation group were treated with bevacizumab injection, based on the treatment in the control group.21 days was a cycle of chemotherapy, and both groups were treated for at least 4 cycles.After 6 cycles of chemotherapy, operation was carried out, following TEM principle.The short-term and long-term prognosis, rate of R0 resection, the incidence of postoperative complications and side effects of chemotherapy were compared between the two groups.ResultsThere was no significant difference between the two groups in the good response rate of chemotherapy, the rate of R0 resection, the incidence of postoperative complications, the 1-year and 3-year survival rates and 1-year disease-free survival rate.The incidence rates of gastrointestinal reactions and bone marrow suppression in the observation group were 52.5% and 52.5%, respectively while in the control group were 25.0% and 20.0%, respectively (P<0.05), but there was no significant difference in the incidence rates of grade Ⅲ~Ⅳ gastrointestinal reaction and bone marrow suppression between the observation group and the control group (5.0% and 15.0% vs 2.5% and 5.0%).The 3-year disease-free survival rate of the observation group was higher than that of the control group (82.5% vs 60.0%) (P<0.05).ConclusionThe application of bevacizumab combined with preoperative FOLFOX chemotherapy in the treatment of LARC can improve the 3-year disease-free survival rate, without increasing postoperative adverse reactions and serious side effects of chemotherapy.
